Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumor or Hematologic Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Early research (Phase 1)Study completedNCT00458731
What this trial is testing

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Who this might be right for
Adult Grade III Lymphomatoid GranulomatosisAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma+59 more
National Cancer Institute (NCI) 57
Early research (Phase 1)Study completedNCT01457417
What this trial is testing

DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Who this might be right for
Multiple MyelomaSolid TumorsNon-Small Cell Lung Cancer
Leap Therapeutics, Inc. 32
Early research (Phase 1)Study completedNCT00004258
What this trial is testing

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Indiana University 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439292
What this trial is testing

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 44
Early research (Phase 1)UnknownNCT04481607
What this trial is testing

Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

Who this might be right for
Advanced Solid Tumor or Hematologic Tumor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 96
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Ended earlyNCT04214093
What this trial is testing

AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Who this might be right for
Advanced Solid TumorsLymphomaMultiple Myeloma+1 more
AstraZeneca 9
Large-scale testing (Phase 3)WithdrawnNCT05403580
What this trial is testing

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm
Mayo Clinic
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385483
What this trial is testing

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 19
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT00082823
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357988
What this trial is testing

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm+3 more
National Cancer Institute (NCI) 34
Early research (Phase 1)Study completedNCT01844869
What this trial is testing

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Who this might be right for
Hematologic MalignanciesSolid Tumors
Teva Branded Pharmaceutical Products R&D, Inc. 6